Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 9/20 | 0.47 |
| ▸ | ATF1 | P18846 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | JUN | P05412 | 4/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.42 |
| ▸ | RELA | Q04206 | 4/20 | 0.42 |
| ▸ | XPO1 | O14980 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL4593114 | 0.98 | MAPT (0.56) | MAPTGAAALDH1A1KMT2AKDM4E | |
| SCHEMBL4592592 | 0.83 | KDM4E (0.72) | MAPTALDH1A1KDM4ENFKB1ATF1 | |
| SCHEMBL15038313 | 0.83 | KDM4E (0.72) | MAPTGAAALDH1A1KMT2AKDM4E | |
| SCHEMBL473934 | 0.83 | ATF1 (0.62) | MAPTGAAALDH1A1KMT2AKDM4E | |
| SCHEMBL1759818 | 0.83 | MAPT (0.53) | MAPTGAAALDH1A1KMT2AKDM4E | |
| Water SCHEMBL4592788 | 0.82 | KDM4E (0.71) | MAPTALDH1A1KDM4ENFKB1ATF1 | |
| SCHEMBL6475927 | 0.80 | MAPT (0.60) | MAPTGAAALDH1A1KMT2AKDM4E | |
| SCHEMBL9564859 | 0.80 | XPO1 (0.46) | MAPTKDM4ENFKB1ATF1JUN | |
| SCHEMBL9565080 | 0.78 | NFKB1 (0.42) | MAPTKDM4ENFKB1ATF1LMNA | |
| Isoorotic Acid Methyl Ester SCHEMBL19303459 | 0.78 | TSHR (0.41) | GAAALDH1A1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101056863-B | Process for the production of pyrimidine-5-carboxylates | LONZA AG | 2011-04-13 | — | — | CN | disclosed |
| US-20080119651-A1 | one pot reaction without isolating intermediates; reacting oxoalkonate with urea, trimethyl orthoformate in methanol or ethanol to yield a 2-acyl-3-ureidoacrylate, reacting intermediate with 2-hydroxypyrimidine-5-carboxylate in presence of alkali alkoxide, convering it to halo compds. with PO2Cl or SOCl2 | LONZA AG (CH) | 2008-05-22 | — | — | US | disclosed |
| EP-1809609-B1 | PROCESS FOR THE PRODUCTION OF PYRIMIDINE-5-CARBOXYLATES | LONZA AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| CN-101056863-A | Process for the production of pyrimidine-5-carboxylates | LONZA AG (CH) | 2007-10-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119651-A1 | one pot reaction without isolating intermediates; reacting oxoalkonate with urea, trimethyl orthoformate in methanol or ethanol to yield a 2-acyl-3-ureidoacrylate, reacting intermediate with 2-hydroxypyrimidine-5-carboxylate in presence of alkali alkoxide, convering it to halo compds. with PO2Cl or SOCl2 | HPD, DCTD, POLD1 | MAPT 4276/4885GAA 4650/4885ALDH1A1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.